AU2015355188B2 - CAMKK1 as a novel regenerative therapeutic - Google Patents

CAMKK1 as a novel regenerative therapeutic Download PDF

Info

Publication number
AU2015355188B2
AU2015355188B2 AU2015355188A AU2015355188A AU2015355188B2 AU 2015355188 B2 AU2015355188 B2 AU 2015355188B2 AU 2015355188 A AU2015355188 A AU 2015355188A AU 2015355188 A AU2015355188 A AU 2015355188A AU 2015355188 B2 AU2015355188 B2 AU 2015355188B2
Authority
AU
Australia
Prior art keywords
camkk1
tissue
organ
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015355188A
Other languages
English (en)
Other versions
AU2015355188A1 (en
Inventor
Matthew Kiedrowski
Maritza Mayorga
Marc S. Penn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northeast Ohio Medical University
Summa Health System
Original Assignee
Northeast Ohio Medical University
Summa Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northeast Ohio Medical University, Summa Health System filed Critical Northeast Ohio Medical University
Publication of AU2015355188A1 publication Critical patent/AU2015355188A1/en
Application granted granted Critical
Publication of AU2015355188B2 publication Critical patent/AU2015355188B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11017—Ca2+/Calmodulin-dependent protein kinase (2.7.11.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
AU2015355188A 2014-12-01 2015-12-01 CAMKK1 as a novel regenerative therapeutic Active AU2015355188B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086026P 2014-12-01 2014-12-01
US62/086,026 2014-12-01
PCT/US2015/063118 WO2016089826A1 (en) 2014-12-01 2015-12-01 Camkk1 as a novel regenerative therapeutic

Publications (2)

Publication Number Publication Date
AU2015355188A1 AU2015355188A1 (en) 2017-07-20
AU2015355188B2 true AU2015355188B2 (en) 2021-08-26

Family

ID=56092307

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015355188A Active AU2015355188B2 (en) 2014-12-01 2015-12-01 CAMKK1 as a novel regenerative therapeutic

Country Status (12)

Country Link
US (2) US11273208B2 (cg-RX-API-DMAC7.html)
EP (2) EP3940068A1 (cg-RX-API-DMAC7.html)
JP (2) JP6893873B2 (cg-RX-API-DMAC7.html)
KR (3) KR102236843B1 (cg-RX-API-DMAC7.html)
AU (1) AU2015355188B2 (cg-RX-API-DMAC7.html)
CA (1) CA3007055C (cg-RX-API-DMAC7.html)
CL (1) CL2017001390A1 (cg-RX-API-DMAC7.html)
CR (1) CR20170301A (cg-RX-API-DMAC7.html)
IL (2) IL252612B (cg-RX-API-DMAC7.html)
RU (1) RU2017122817A (cg-RX-API-DMAC7.html)
UA (1) UA124450C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016089826A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089826A1 (en) 2014-12-01 2016-06-09 Summa Health Camkk1 as a novel regenerative therapeutic
EP3781182A4 (en) 2018-04-18 2021-11-17 Summa Health COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426206B1 (en) * 2000-11-13 2002-07-30 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US20090246179A1 (en) * 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072115A2 (en) 2001-03-09 2002-09-19 Board Of Regents, The University Of Texas System Vectors, compositions and methods for treating a vascular disorder
US7776564B2 (en) 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
US7764995B2 (en) * 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US8173118B2 (en) * 2004-07-30 2012-05-08 Mayo Foundation For Medical Education And Research Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin
CN101103101B (zh) 2004-09-24 2012-10-10 成血管细胞系统公司 增强间充质前体细胞（mpc）的增生和/或存活的方法
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
EP3039124A1 (en) * 2013-08-29 2016-07-06 Stempeutics Research Private Limited Stromal cells derived conditioned medium, method of obtaining said conditioned medium compositions, formulations and applications thereof
WO2016089826A1 (en) * 2014-12-01 2016-06-09 Summa Health Camkk1 as a novel regenerative therapeutic
HK1246180A1 (zh) 2014-12-31 2018-09-07 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426206B1 (en) * 2000-11-13 2002-07-30 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US20090246179A1 (en) * 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ENSLEN, H et al., "Regulation of Mitogen-Activated Protein Kinases by a Calcium/Calmodulin- dependent Protein Kinase Cascade.", Proc. Natl. Acad. Sci. USA., (1996-10), vol. 93, pages 10803 - 10808 *
GNECCHI M ET AL, "Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement", THE FASEB JOURNAL, (2006-01-01), vol. 20, pages 661 - 669 *
LEO TIMMERS, SAI KIANG LIM, FATIH ARSLAN, JEFFREY S. ARMSTRONG, IMO E. HOEFER, PIETER A. DOEVENDANS, JAN J. PIEK, REIDA MENSHAWE E: "Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium.", STEM CELL RESEARCH, ELSEVIER, NL, vol. 1, no. 2, 1 June 2008 (2008-06-01), NL, pages 129 - 137, XP002635356, ISSN: 1873-5061, DOI: 10.1016/J.SCR.2008.02.002 *
MARITZA E. MAYORGA ET AL, "Central Role for Disabled-2 in Mesenchymal Stem Cardiac Protein Expression and Functional Consequences After Engraftment in Acute Myocardial Infarction", STEM CELLS DEV, 2011, vol. 20, no. 4, pages 681 - 693 *
MARITZA E. MAYORGA ET AL, "miR-145 is differentially regulated by TGF-[beta]1 and ischaemia and targets Disabled-2 expression and wnt/[beta]-catenin activity", JCMM, 2015, vol. 16, no. 5, pages 1106 - 1113 *
YANO, S et al., "Functional Proteins Involved in Regulation of Intracellular Ca2+ for Drug . Development: Role of Calcium/Calmodulin-Dependent Protein Kinases in Ischemic Neuronal Death.", J Pharmacol. Sci., (2005), vol. 97, pages 351 - 354 *

Also Published As

Publication number Publication date
JP2021098717A (ja) 2021-07-01
EP3227441B1 (en) 2021-06-30
WO2016089826A1 (en) 2016-06-09
EP3227441A1 (en) 2017-10-11
US20170340712A1 (en) 2017-11-30
KR20210010662A (ko) 2021-01-27
CA3007055A1 (en) 2016-06-09
CA3007055C (en) 2023-08-01
IL252612B (en) 2021-07-29
UA124450C2 (uk) 2021-09-22
KR102460983B1 (ko) 2022-10-31
JP6893873B2 (ja) 2021-06-23
KR102236843B1 (ko) 2021-04-07
CR20170301A (es) 2018-02-01
EP3940068A1 (en) 2022-01-19
US11273208B2 (en) 2022-03-15
KR20220151004A (ko) 2022-11-11
AU2015355188A1 (en) 2017-07-20
RU2017122817A3 (cg-RX-API-DMAC7.html) 2019-06-11
KR20170088988A (ko) 2017-08-02
BR112017011490A2 (pt) 2018-02-27
JP2018502838A (ja) 2018-02-01
CL2017001390A1 (es) 2018-05-11
RU2017122817A (ru) 2019-01-10
IL284408B (en) 2022-06-01
KR102610068B1 (ko) 2023-12-06
US20220233653A1 (en) 2022-07-28
IL252612A0 (en) 2017-07-31
EP3227441A4 (en) 2018-08-15
IL284408A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
EP2327781A1 (en) Micro-RNA and tissue repair
CN113166777B (zh) 含有AIMP2-DX2和miR-142的靶核酸的载体及其用途
US10729789B2 (en) Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
US20220233653A1 (en) Camkk1 as a novel regenerative therapeutic
US20180271942A1 (en) Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage
CN102046810A (zh) 血管生成抑制
KR20180124980A (ko) 뉴런 과흥분성 치료를 위한 방법 및 조성물
Zhao et al. pNNS‐Conjugated Chitosan Mediated IGF‐1 and miR‐140 Overexpression in Articular Chondrocytes Improves Cartilage Repair
JP2011504375A (ja) 細胞の中に核酸を導入する医薬組成物及びその方法
WO2017029206A1 (en) Use of k2p potassium channel for altering the electrophysiology of the heart
US10537591B2 (en) Method for promoting muscle regeneration
US11566247B2 (en) Modulation of alternative MDM2 splicing
WO2021148763A1 (en) Peptide inhibitors of guanine nucleotide exchange factor-h1
EP2586865B1 (en) Recombinant vector for suppressing proliferation of human papillomavirus cell including adenylate cyclase activating polypeptide 1 (pituitary) gene and pharmaceutical composition for treating human papillomavirus
BR112017011490B1 (pt) Uso de plasmídeo ou vetor viral, compreendendo um ácido nucleico que codifica camkk1
Sasipong Targeted overexpression of relaxin receptor 1 (RXFP1) with chronic administration of relaxin as a novel inotropic approach for heart failure treatment
WO2007026973A1 (en) Recombinant adeno-associated virus containing vegfr truncated cdna and gene therapeutic agent for cancer comprising the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)